When does Nplate’s loss of exclusivity happen?
Nplate (romiplostim) loses regulatory exclusivity when the period preventing generic or biosimilar competition expires in a specific country. Exclusivity timing varies by jurisdiction and by the type of protection being counted (for example, “data exclusivity” versus “market exclusivity,” and patent term versus regulatory exclusivity).
The provided information doesn’t include the jurisdiction, nor the specific exclusivity type or dates, so the exact “loss of exclusivity” timing for Nplate can’t be stated from what’s given.
What kind of “exclusivity” might people mean for Nplate?
People usually mean one of these, and each can expire on a different date:
- Patent expiry (including any patent term extensions or pediatric extensions).
- Regulatory data exclusivity (time during which regulators may rely on the innovator’s clinical data).
- Market exclusivity (time during which competing products may be blocked even if application requirements are met).
Without the country and which of these you mean, the answer will differ.
If you tell me your country, can you give the exact date?
Yes—if you share the country/region (for example, US, EU, UK, Canada, Australia) and whether you mean patent expiry or regulatory exclusivity, the timing can be pinned down more precisely.
What else should you check besides exclusivity?
Even after exclusivity expires, competitors may still be delayed by:
- Still-in-force patents covering specific formulations or dosing regimens.
- Ongoing litigation that blocks launches.
- Regulatory requirements that may not be satisfied until later.
If you want, tell me the region and whether you’re asking about biosimilar/generic entry timing, and I can map which protections typically control that date.
Sources
No sources were provided in the prompt.